PRX-03140
As of the edition of 20 October 2026, PRX-03140 is a small molecule: went quiet in 2013; acts on HTR4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2013
- Kind
- Small molecule
- Registered trials
- 4, 2 stopped early
- Disease areas
- Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of PRX-03140.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HTR4 | 5-hydroxytryptamine receptor 4 | Q13639 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 1 | 0 | 2 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Epix Pharmaceuticals | Lead sponsor of trials | 2006 to now |
| Alachua Government | Lead sponsor of trials | 2012 to now |